Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma

Ahmad M. Mansour, J Fernando Arevalo, Eman Al Kahtani, Hernando Zegarra, Emad Abboud, Rajiv Anand, Hamid Ahmadieh, Robert A. Sisk, Salman Mirza, Samuray Tuncer, Amparo Navea Tejerina, Jorge Mataix, Francisco J. Ascaso, Jose S. Pulido, Rainer Guthoff, Winfried Goebel, Young Jung Roh, Alay S. Banker, Ronald C. Gentile, Isabel Alonso Martinez & 7 others Rodney Morris, Neeraj Panday, Park Jung Min, Emilie Mercé, Timothy Y Y Lai, Vicky Massoud, Nicola G. Ghazi

Research output: Contribution to journalArticle

Abstract

We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0. 001), 105.3 microns at 1 year (n = 10; P = 0. 03), and 157.6 microns at 2 years (n = 7; P = 0. 08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P <0. 001), 2.8 lines (n = 20; P = 0. 01) at 1 year, and 3.1 lines (n = 13; P = 0. 049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.

Original languageEnglish (US)
Article number210458
JournalJournal of Ophthalmology
Volume2014
DOIs
StatePublished - 2014

Fingerprint

Endothelial Growth Factors
Osteoma
Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Injections
Matched-Pair Analysis
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma. / Mansour, Ahmad M.; Arevalo, J Fernando; Al Kahtani, Eman; Zegarra, Hernando; Abboud, Emad; Anand, Rajiv; Ahmadieh, Hamid; Sisk, Robert A.; Mirza, Salman; Tuncer, Samuray; Navea Tejerina, Amparo; Mataix, Jorge; Ascaso, Francisco J.; Pulido, Jose S.; Guthoff, Rainer; Goebel, Winfried; Roh, Young Jung; Banker, Alay S.; Gentile, Ronald C.; Martinez, Isabel Alonso; Morris, Rodney; Panday, Neeraj; Min, Park Jung; Mercé, Emilie; Lai, Timothy Y Y; Massoud, Vicky; Ghazi, Nicola G.

In: Journal of Ophthalmology, Vol. 2014, 210458, 2014.

Research output: Contribution to journalArticle

Mansour, AM, Arevalo, JF, Al Kahtani, E, Zegarra, H, Abboud, E, Anand, R, Ahmadieh, H, Sisk, RA, Mirza, S, Tuncer, S, Navea Tejerina, A, Mataix, J, Ascaso, FJ, Pulido, JS, Guthoff, R, Goebel, W, Roh, YJ, Banker, AS, Gentile, RC, Martinez, IA, Morris, R, Panday, N, Min, PJ, Mercé, E, Lai, TYY, Massoud, V & Ghazi, NG 2014, 'Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma', Journal of Ophthalmology, vol. 2014, 210458. https://doi.org/10.1155/2014/210458
Mansour, Ahmad M. ; Arevalo, J Fernando ; Al Kahtani, Eman ; Zegarra, Hernando ; Abboud, Emad ; Anand, Rajiv ; Ahmadieh, Hamid ; Sisk, Robert A. ; Mirza, Salman ; Tuncer, Samuray ; Navea Tejerina, Amparo ; Mataix, Jorge ; Ascaso, Francisco J. ; Pulido, Jose S. ; Guthoff, Rainer ; Goebel, Winfried ; Roh, Young Jung ; Banker, Alay S. ; Gentile, Ronald C. ; Martinez, Isabel Alonso ; Morris, Rodney ; Panday, Neeraj ; Min, Park Jung ; Mercé, Emilie ; Lai, Timothy Y Y ; Massoud, Vicky ; Ghazi, Nicola G. / Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma. In: Journal of Ophthalmology. 2014 ; Vol. 2014.
@article{7eaebf9d610c4b34b4be150aaf316fa2,
title = "Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma",
abstract = "We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0. 001), 105.3 microns at 1 year (n = 10; P = 0. 03), and 157.6 microns at 2 years (n = 7; P = 0. 08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P <0. 001), 2.8 lines (n = 20; P = 0. 01) at 1 year, and 3.1 lines (n = 13; P = 0. 049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.",
author = "Mansour, {Ahmad M.} and Arevalo, {J Fernando} and {Al Kahtani}, Eman and Hernando Zegarra and Emad Abboud and Rajiv Anand and Hamid Ahmadieh and Sisk, {Robert A.} and Salman Mirza and Samuray Tuncer and {Navea Tejerina}, Amparo and Jorge Mataix and Ascaso, {Francisco J.} and Pulido, {Jose S.} and Rainer Guthoff and Winfried Goebel and Roh, {Young Jung} and Banker, {Alay S.} and Gentile, {Ronald C.} and Martinez, {Isabel Alonso} and Rodney Morris and Neeraj Panday and Min, {Park Jung} and Emilie Merc{\'e} and Lai, {Timothy Y Y} and Vicky Massoud and Ghazi, {Nicola G.}",
year = "2014",
doi = "10.1155/2014/210458",
language = "English (US)",
volume = "2014",
journal = "Journal of Ophthalmology",
issn = "2090-004X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma

AU - Mansour, Ahmad M.

AU - Arevalo, J Fernando

AU - Al Kahtani, Eman

AU - Zegarra, Hernando

AU - Abboud, Emad

AU - Anand, Rajiv

AU - Ahmadieh, Hamid

AU - Sisk, Robert A.

AU - Mirza, Salman

AU - Tuncer, Samuray

AU - Navea Tejerina, Amparo

AU - Mataix, Jorge

AU - Ascaso, Francisco J.

AU - Pulido, Jose S.

AU - Guthoff, Rainer

AU - Goebel, Winfried

AU - Roh, Young Jung

AU - Banker, Alay S.

AU - Gentile, Ronald C.

AU - Martinez, Isabel Alonso

AU - Morris, Rodney

AU - Panday, Neeraj

AU - Min, Park Jung

AU - Mercé, Emilie

AU - Lai, Timothy Y Y

AU - Massoud, Vicky

AU - Ghazi, Nicola G.

PY - 2014

Y1 - 2014

N2 - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0. 001), 105.3 microns at 1 year (n = 10; P = 0. 03), and 157.6 microns at 2 years (n = 7; P = 0. 08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P <0. 001), 2.8 lines (n = 20; P = 0. 01) at 1 year, and 3.1 lines (n = 13; P = 0. 049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.

AB - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0. 001), 105.3 microns at 1 year (n = 10; P = 0. 03), and 157.6 microns at 2 years (n = 7; P = 0. 08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P <0. 001), 2.8 lines (n = 20; P = 0. 01) at 1 year, and 3.1 lines (n = 13; P = 0. 049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.

UR - http://www.scopus.com/inward/record.url?scp=84937064814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937064814&partnerID=8YFLogxK

U2 - 10.1155/2014/210458

DO - 10.1155/2014/210458

M3 - Article

VL - 2014

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

SN - 2090-004X

M1 - 210458

ER -